Antipneumolysin antibody titers in HIV-seropositive injection drug users before and after pneumococcal bacteremia

Jeffrey H. Sullivan, Timothy J. Mitchell, Mark C. Steinhoff

Research output: Contribution to journalArticlepeer-review

Abstract

Lower baseline antipneumolysin antibody (α-PLY) levels have been found in populations with a higher incidence of pneumococcal infections. To determine whether predisease α-PLY titer is associated with invasive pneumococcal disease in HIV-seropositive injection drug users (IDU), we utilized a prospective cohort of IDU in Baltimore to compare α-PLY titers before bacteremia in 28 HIV-seropositive IDU cases with α-PLY titers in 56 matched (CD4 and seroconversion date) HIV-seropositive IDU control subjects and 28 matched (calendar time) HIV-seronegative IDU control subjects remaining free of pneumococcal disease. We also compared the postinfection fold-rise of α-PLY titers in cases relative to the change in α-PLY titers in control subjects during the same interval; α-PLY titers were measured using quantitative ELISA, and functional activity was assessed using antihemolysin assays. Predisease α-PLY titer did not differ between cases (66 units) and HIV-seropositive control subjects (70 units, p = 0.56) or HIV-seronegative control subjects (80 units, p = 0.10). There was a significant difference in fold-rise of α-PLY titers post-disease between cases (1.18) and HIV-seronegative control subjects (0.76), p = 0.03. Baseline α-PLY titers do not differ significantly between HIV-seropositive IDU who develop pneumococcal bacteremia from HIV-seropositive and HIV-seronegative IDU control subjects remaining free of severe pneumococcal disease.

Original languageEnglish (US)
Pages (from-to)680-684
Number of pages5
JournalAmerican journal of respiratory and critical care medicine
Volume163
Issue number3 I
DOIs
StatePublished - 2001
Externally publishedYes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Fingerprint

Dive into the research topics of 'Antipneumolysin antibody titers in HIV-seropositive injection drug users before and after pneumococcal bacteremia'. Together they form a unique fingerprint.

Cite this